Next Article in Journal
The Role of Mitochondria in Acute Kidney Injury and Chronic Kidney Disease and Its Therapeutic Potential
Next Article in Special Issue
Fat of the Gut: Epithelial Phospholipids in Inflammatory Bowel Diseases
Previous Article in Journal
Placental Ischemia Says “NO” to Proper NOS-Mediated Control of Vascular Tone and Blood Pressure in Preeclampsia
Review

Multi-Omics Analysis of Gut Microbiota in Inflammatory Bowel Diseases: What Benefits for Diagnostic, Prognostic and Therapeutic Tools?

by 1,2,†, 3,†, 1,2,4,* and 2,*
1
Gastroenterology, Hepatology, Nutrition, Diabetology and Hereditary Metabolic Diseases Unit, Children’s Hospital, CHU de Toulouse, 31300 Toulouse, France
2
IRSD, University of Toulouse, INSERM, INRAE, ENVT, UPS, 31024 Toulouse, France
3
Department of Nephrology and Organ Transplantation, Rangueil Hospital, CHU de Toulouse, 31300 Toulouse, France
4
Gastroenterology, Hepatology, Nutrition, Diabetology and Hereditary Metabolic Diseases Unit 330, Avenue de Grande-Bretagne, TSA 70034, CEDEX 09, 31059 Toulouse, France
*
Authors to whom correspondence should be addressed.
These authors contributed equally to this work.
Academic Editor: Giuseppe Esposito
Int. J. Mol. Sci. 2021, 22(20), 11255; https://doi.org/10.3390/ijms222011255
Received: 23 September 2021 / Revised: 12 October 2021 / Accepted: 15 October 2021 / Published: 19 October 2021
(This article belongs to the Special Issue Inflammatory Bowel Diseases: Pathogenesis and Future Developments)
Inflammatory bowel diseases (IBDs), which include Crohn’s disease and ulcerative colitis, are multifactorial diseases that involve in particular a modification of the gut microbiota, known as dysbiosis. The initial sets of metataxonomic and metagenomic data first made it possible to approximate the microbiota profile in IBD. In addition, today the new ‘omics’ techniques have enabled us to draw up a functional and integrative map of the microbiota. The key concern in IBD is to develop biomarkers that allow us to assess the activity of the disease and predict the complications and progression, while also guiding the therapeutic care so as to develop personalized medicine. In this review, we present all of the latest discoveries on the microbiota provided by “omics” and we outline the benefits of these techniques in developing new diagnostic, prognostic and therapeutic tools. View Full-Text
Keywords: inflammatory bowel disease; Crohn’s disease; ulcerative colitis; microbiota; omics inflammatory bowel disease; Crohn’s disease; ulcerative colitis; microbiota; omics
Show Figures

Figure 1

MDPI and ACS Style

Lacroix, V.; Cassard, A.; Mas, E.; Barreau, F. Multi-Omics Analysis of Gut Microbiota in Inflammatory Bowel Diseases: What Benefits for Diagnostic, Prognostic and Therapeutic Tools? Int. J. Mol. Sci. 2021, 22, 11255. https://doi.org/10.3390/ijms222011255

AMA Style

Lacroix V, Cassard A, Mas E, Barreau F. Multi-Omics Analysis of Gut Microbiota in Inflammatory Bowel Diseases: What Benefits for Diagnostic, Prognostic and Therapeutic Tools? International Journal of Molecular Sciences. 2021; 22(20):11255. https://doi.org/10.3390/ijms222011255

Chicago/Turabian Style

Lacroix, Vickie, Alexis Cassard, Emmanuel Mas, and Frederick Barreau. 2021. "Multi-Omics Analysis of Gut Microbiota in Inflammatory Bowel Diseases: What Benefits for Diagnostic, Prognostic and Therapeutic Tools?" International Journal of Molecular Sciences 22, no. 20: 11255. https://doi.org/10.3390/ijms222011255

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop